Canada - English - Health Canada

sandoz canada incorporated - rituximab - solution - 10mg - rituximab 10mg - antineoplastic agents

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

roche products (pty) ltd - infusion (parenteral) - see ingredients - each 1,0 ml solution contains rituximab 10,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

roche products (pty) ltd - infusion (parenteral) - see ingredients - each 1,0 ml solution contains rituximab 10,0 mg

Canada - English - Health Canada

amgen canada inc - rituximab - solution - 10mg - rituximab 10mg - antineoplastic agents

Israel - English - Ministry of Health

merck serono ltd - cetuximab - solution for infusion - cetuximab 5 mg/ml - cetuximab - cetuximab - erbitux® is indicated for the treatment of patients with epidermal growth factor receptor (egfr) - expressing, ras wild-type metastatic colorectal cancer• in combination with irinotecan-based chemotherapy• in first-line in combination with folfox• as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecanerbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (scchn)• in combination with radiation therapy for locally advanced disease• in combination with platinum-based chemotherapy for recurrent and/or metastatic disease• as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease

European Union - English - EMA (European Medicines Agency)

merck europe b.v.  - cetuximab - head and neck neoplasms; colorectal neoplasms - antineoplastic agents - erbitux is indicated for the treatment of patients with epidermal growth factor receptor (egfr)-expressing, ras wild-type metastatic colorectal cancer:in combination with irinotecan-based chemotherapy;in first-line in combination with folfox;as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.for details, see section 5.1.erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck:in combination with radiation therapy for locally advanced disease;in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

European Union - English - EMA (European Medicines Agency)

united therapeutics europe ltd - dinutuximab - neuroblastoma - antineoplastic agents - unituxin is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months to 17years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (asct). it is administered in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin-2 (il-2), and isotretinoin.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - rituximab, quantity: 1600 mg - injection - excipient ingredients: vorhyaluronidase alfa; histidine; histidine hydrochloride; trehalose dihydrate; methionine; polysorbate 80; water for injections - mabthera sc 1600 mg is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.